covid-19 vaccine after a participant fell ill, the second time that a front-runner developer has paused testing in the race to create viable immunization against the virus.The participant’s illness is being evaluated, the New Brunswick, New Jersey-based company, said late on Monday, adding that it would share information after further investigation.
J&J shares fell 2.4% in trading before US exchanges opened. The vaccine is undergoing tests involving as many as 60,000 volunteers from Peru to South Africa.J&J is racing along with rivals Moderna Inc., Pfizer Inc.